ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.

Geraldine O'Sullivan Coyne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.